
MLYS Stock Forecast & Price Target
MLYS Analyst Ratings
Bulls say
Mineralys Therapeutics, Inc. is gaining positive market sentiment due to the demonstrated efficacy of its product candidate, lorundrostat, which has achieved significant blood pressure reductions of 8-12 mmHg in patients with uncontrolled and resistant hypertension. The company's pivotal trial results highlight a robust placebo-adjusted reduction of 9.1 mmHg at 6 weeks and 11.7 mmHg at 12 weeks, with a favorable hyperkalemia rate, suggesting a strong safety profile that could enhance adoption among healthcare providers. Furthermore, the anticipated clinical success of lorundrostat supports its potential as a daily-use treatment option, positioning Mineralys favorably in a market with significant unmet needs in hypertension management.
Bears say
Mineralys Therapeutics Inc reported a significant net loss of $48.9 million for the fourth quarter of 2024 and $177.8 million for the entire year, indicating a concerning financial trajectory with losses per share reaching $0.98 and $3.66 respectively. The company's outlook is shadowed by crucial risks, including the potential failure of its drug candidates to meet commercial revenue estimates, which could be impacted by factors such as market size, penetration rates, and pricing strategies. Furthermore, the company's ability to secure adequate capital resources for ongoing operations and to advance its development and commercialization programs remains a critical concern, potentially jeopardizing its long-term viability.
This aggregate rating is based on analysts' research of Mineralys Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
MLYS Analyst Forecast & Price Prediction
Start investing in MLYS
Order type
Buy in
Order amount
Est. shares
0 shares